MorphoSys'
clinical pipeline

You are here

Based on our advanced antibody research, we are developing novel therapies for people with cancer and autoimmune diseases. Here you can find an overview of the clinical studies on our own drug candidates and the most advanced clinical programs of our partners.

Our clinical pipeline

  • Phase 1
  • Phase 2
  • Phase 3
  • Market
Program
Partner
Indication
Phase

Partner

Incyte Corporation*

Indication

Phase

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only – accelerated approval)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (B-MIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Relapsed or refractory follicular or marginal zone lymphoma (FL; MZL) (inMIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Diffuse large B-cell lymphoma (DLBCL) (frontMIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (COSMOS)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Diffuse large B-cell lymphoma (DLBCL) (firstMIND)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

*Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.

  • MOR208 (former XmAb®5574)
  • INN: tafasitamab
  • Target: CD19

Partner

 

Indication

Phase

Anti-PLA2R-positive membranous nephropathy (New-PLACE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Anti-PLA2R-positive membranous nephropathy (M-PLACE)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

* Felzartamab (MOR202/TJ202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.

  • A fully human HuCAL antibody
  • Target: CD38

* Tafasitamab: Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.

Clinical programs developed by our partners (selection)

  • Phase 1
  • Phase 2
  • Phase 3
  • Market
Program
Partner
Indication
Phase

Tremfya® (guselkumab)

Partner

Janssen/J&J

Indication

Phase

Plaque psoriasis
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Psoriatic arthitis (PsA)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Palmoplantar pustolosis (Japan only)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Palmoplantar-non-pustular psoriasis (G-PLUS)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Chronic plaque psoriasis (pediatric participants) (PROTOSTAR)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Crohn's disease (GALAXI)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Ulcerative colitis (QUASAR)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Familial adenomatous polyposis
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IL23p19
  • Aliases: CNTO1959

Additional Information:

Felzartamab (MOR202)

Partner

I-Mab Biopharma*

Indication

Phase

Multiple myeloma (MM) (combo with lenalidomide)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Multiple myeloma (MM)*
Phase 1 Phase 2 (Current Phase) Phase 3 Market

Otilimab (MOR103/GSK3196165)

Partner

GlaxoSmithKline

Indication

Phase

Rheumatoid arthritis (contRAst 1-3)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Severe pulmonary COVID-19 related disease (OSCAR)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

*Fully outlicensed to GlaxoSmithKline.

  • A fully human HuCAL antibody
  • Target: GM-CSF

Gantenerumab

Partner

Roche

Indication

Phase

Early Alzheimer's disease (GRADUATE 1+2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Mild Alzheimer's disease (Marguerite RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Prodromal Alzheimer's disease (Scarlett RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Rollover study on long-term administration of gantenerumab
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Alzheimer's disease (Brain Shuttle Gantenerumab, RG6102)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Amyloid-beta

Additional Information:

Anetumab ravtansine

Partner

Bayer AG

Indication

Phase

Mesothelioma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Cancer, multi-indications
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL-based antibody drug conjugate
  • Target: Mesothelin
  • Alias: BAY94-9343​

Additional Information:

Ianalumab (VAY736)

Partner

Novartis

Indication

Phase

ADCC mediated B cell depletion & BAFF-R blockade (AMBER)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Idiopathic pulmonary fibrosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Systemic Lupus Erythematosus (SLE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: BAFF-R

Additional information:

Setrusumab (BPS804)

Partner

Novartis/Mereo/Ultragenyx

Indication

Phase

Brittle bone disease (Type I, III, IV) (ASTEROID)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: Sclerostin

Additional information:

Bimagrumab

Partner

Novartis

Indication

Phase

Type 2 diabetes
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: ActRIIB
  • Aliases: BYM338

Additional information:

Utomilumab (PF-05082566)

Partner

Pfizer

Indication

Phase

Breast cancer (combo with avelumab) (InCITe)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors (combo with ISA101b vaccination)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Advanced Malignancies (combo with avelumab, PF-04518600 & CMP-001 (TLR9 agonist)) (JAVELIN Medley)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Advanced malignancies (combo with avelumab & PF-04518600)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Refractory large B cell lymphoma (combo with Axicabtagene ciloleucel) (ZUMA-11)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: 4-1BB (CD137)
  • Alias: PF-05082566

Additional Information:

Xentuzumab (BI-836845)

Partner

Boehringer Ingelheim

Indication

Phase

Breast cancer
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Castration-resistant prostate cancer (CRPC) (combo with enzalutamide)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IGF-1

Additional Information:

MOR210

Partner

I-Mab Biopharma*

Indication

Phase

Relapsed or refractory advanced solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market

* I-Mab receives exclusive rights in China, Hong Kong, Macao, Taiwan and South Korea, while MorphoSys retains rights in other parts of the world.

* Felzartamab (MOR202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.
* MOR210: Sublicensed to I-Mab for development in China, Hong Kong, Macao, Taiwan and South Korea.

Physicians and Patients

Physicians interested in learning more about MorphoSys-sponsored clinical trials should contact: medical@morphosys.com.

Patients are kindly asked to contact their treating physicians if they are interested in participating in any of MorphoSys's clinical trials.

Disclaimer
MorphoSys’s product candidates are investigational and are currently not approved for the treatment of any disease or condition anywhere in the world. They cannot be prescribed or purchased for therapy at present.

The MorphoSys website may contain information on drug candidates and clinical trials sponsored by MorphoSys with the intention of increasing the transparency of the company’s clinical research. There is no guarantee any product will be approved in the sought after indication.

Information contained within this website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment.

All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information available through the site. MorphoSys may amend the information at any time without notice.

Tafasitamab
(MOR208)

Visit

Felzartamab
(MOR202)

Visit

Expanded Access to our Investigational Medicinal Products Policy

At MorphoSys, our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.  Before these and all other investigational medicinal products can be made broadly available, the U.S. Food and Drug Administration (FDA) and other health authorities around the world require that they are investigated in clinical trials.  Throughout this process, the safety of patients taking our medicines is of the utmost importance.

Clinical trials are research investigations that are designed to determine if a medicine is safe and effective for patients.

People who choose to participate in clinical trials play an essential role in developing new medicines, particularly for rare diseases and conditions that are especially difficult to treat.  Whenever possible, MorphoSys will refer an individual requesting access to our investigational medicinal products to an appropriate clinical trial. To discuss your eligibility for a MorphoSys clinical trial, please ask your treating physician. In some cases, patients with serious or immediately life-threatening diseases may not be eligible for any clinical trials and may not have other treatment options. Only under exceptional and very specific circumstances, these patients may be able to receive investigational medicinal products outside the clinical trial process.
These patients may be able to receive investigational medicines through “Expanded Access Programs” (EAP) (sometimes referred to as “Compassionate Use”).  

EAPs can be set-up for patients:

  • With serious or life-threatening diseases
  • Who have exhausted all treatment options and
  • Who are not eligible for any clinical trial

MorphoSys is committed to providing access to investigational medicinal products in cooperation with local health authorities and in accordance with our criteria for an EAP. EAPs only apply to investigational medicinal products not yet approved by the local health authorities.

MorphoSys May Consider Providing Participation in an EAP to a Patient if the following Principles Are Observed:

  • Access to the MorphoSys investigational medicinal product is for a patient(s) with a serious or life-threatening condition for whom no other treatment options or clinical trials are available.  If and when appropriate, an EAP is a solution of last resort if regulatory requirements allows.
  • MorphoSys must be conducting research with the requested investigational medicinal product as part of a clinical trial.  Upon commercial availability of the medicine, following local health authority approval, any applicable EAPs will be terminated.
  • Granting participation in a MorphoSys EAP must not interfere in any way with the completion of clinical trials that could support health authority approval of the investigational medicinal product.  Whenever possible, patients requesting access to a MorphoSys investigational medicinal product will be referred to an ongoing clinical trial.
  • Patient must not be eligible for ongoing or pending clinical trials of the investigational medicinal product
  • Potential benefits to the patient seeking access to the investigational medicinal product must outweigh the collective potential risks to the patient.  The patient’s physician must decide whether the potential benefit outweighs the risk of receiving an investigational or unapproved medicine, based on the individual patient’s medical history.
  • Adequate clinical data must exist to support the appropriate dosing, frequency of the investigational medicinal product and duration of treatment.  MorphoSys’ clinical team will determine whether this clinical data is available and is adequate.
  • Sufficient supply of the investigational medicinal product to support the EAP.  Supplying the medicine through the EAP must not compromise the supply of medicine available for active or soon-opening clinical trials.